A new experimental drug called OLN324 has demonstrated superior results compared to a leading eye treatment in treating two common causes of vision loss: diabetic macular edema (DME) and wet age-related macular degeneration (wAMD). In a 20-week clinical trial involving 164 patients, OLN324 achieved faster and more durable improvements in retinal health, required fewer retreatments, and showed sustained vision gains that exceeded the current standard therapy .

What Makes OLN324 Different From Current Treatments?

OLN324 is a next-generation bispecific antibody, meaning it targets two different disease pathways simultaneously rather than just one. Specifically, it blocks both VEGF (vascular endothelial growth factor) and Ang2 (angiopoietin-2), two proteins that drive abnormal blood vessel growth and fluid accumulation in the retina. The drug is also engineered to be smaller and more potent than faricimab (Vabysmo), the current leading treatment for these conditions .

In the JADE trial, all 164 patients initially received three monthly injections of either OLN324 or faricimab, then were monitored for an additional 12 weeks without treatment to assess how long the benefits lasted. This design allowed researchers to measure not just immediate effectiveness, but also durability and the need for retreatment .

How Do the Study Results Compare Between the Two Treatments?

For diabetic macular edema, OLN324 demonstrated meaningfully faster and greater improvements. At the 12-week mark, patients treated with OLN324 showed superior retinal drying, measured by optical coherence tomography (OCT), a non-invasive imaging technique that measures retinal thickness. More importantly, these improvements persisted through week 20, even after treatment had stopped .

The retreatment data tells a compelling story about durability. Among DME patients, 93% of those receiving OLN324 at the 4 mg dose completed 12 weeks of follow-up without needing additional injections, compared to 89% of those receiving faricimab. While this difference may seem modest, it reflects a meaningful reduction in the treatment burden for patients who must travel to eye clinics for injections .

For wet age-related macular degeneration, OLN324 and faricimab showed comparable rapid improvements in retinal fluid reduction through week 12. However, vision gains continued to diverge between the groups from weeks 12 to 20, with OLN324 patients gaining an average of 2.2 more letters on the vision chart by week 20. In practical terms, this means better reading ability and improved quality of life .

A particularly striking finding involved pigment epithelial detachments (PEDs), which are fluid-filled pockets that develop beneath the retina in about 80% of wet AMD patients. OLN324 achieved approximately 50% greater reductions in PED thickness at week 12 compared to faricimab, and these improvements remained more durable through week 20. PEDs are notoriously difficult to treat with current therapies and are associated with subretinal fibrosis, a major cause of late vision loss in AMD .

What About Safety and Side Effects?

Safety data favored OLN324 across the board. The drug demonstrated zero cases of intraocular inflammation (swelling inside the eye) throughout the entire 20-week study, compared to one case in a faricimab-treated patient. There were also no cases of retinal vasculitis, a serious inflammatory condition affecting blood vessels in the retina .

"These new JADE study data further strengthen the differentiated profile of OLN324, highlighting its robust anatomic efficacy and durability across both DME and wAMD. Combined with a favorable safety profile, these results underscore OLN324's potential to become a first-line treatment option for these vision-threatening diseases," said Jason Ehrlich, M.D., Ph.D., Co-founder and Chief Executive Officer of Ollin Biosciences.

Jason Ehrlich, M.D., Ph.D., Co-founder and Chief Executive Officer of Ollin Biosciences

Why Does This Matter for Patients With Vision Loss?

Diabetic macular edema and wet age-related macular degeneration are leading causes of vision loss in working-age adults and seniors, respectively. Current treatments require frequent eye injections, sometimes monthly, to maintain vision. Any drug that reduces treatment frequency while improving outcomes represents a significant advance in quality of life .

The particular advantage in treating pigment epithelial detachments is noteworthy because these structures have proven resistant to current therapies. By achieving greater and more durable PED flattening, OLN324 may help prevent the subretinal scarring that leads to permanent vision loss in the later stages of AMD .

Steps to Understanding Your Eye Treatment Options

• Know Your Diagnosis: Ask your eye doctor whether you have diabetic macular edema, wet age-related macular degeneration, or another retinal condition, as treatment approaches differ significantly between diseases.
• Discuss Treatment Frequency: Inquire about how often you would need injections with your current treatment and whether newer options might reduce the number of visits required.
• Ask About Clinical Trials: If you have DME or wAMD, ask whether you might be eligible for clinical trials of newer therapies like OLN324, which may offer access to more advanced treatments.
• Monitor Retinal Health: Ensure your eye doctor performs regular OCT imaging to track retinal thickness and fluid levels, as these measurements guide treatment decisions.
• Manage Underlying Conditions: For diabetic macular edema, tight control of blood sugar and blood pressure significantly impacts treatment outcomes and disease progression.

What's Next for OLN324?

Based on these promising Phase 1b results, Ollin Biosciences and its partner Innovent Biologics are advancing OLN324 into global Phase 3 studies, the final stage of testing before regulatory approval. These larger trials are expected to begin in 2026 and will recruit patients from North America, South America, Europe, Japan, China, and South Korea .

"As a field, we've been looking for meaningful advancements that further improve anatomic outcomes in wAMD. These data suggest that OLN324's more potent Ang2 inhibition and smaller molecular format may translate into breaking through the efficacy ceiling experienced with current treatments and offering a clinically-relevant benefit in PED improvement, the most difficult to treat component of wAMD," noted David Eichenbaum, M.D., FASRS, Director of Research, Retina Vitreous Associates of Florida.

David Eichenbaum, M.D., FASRS, Director of Research, Retina Vitreous Associates of Florida

If OLN324 receives regulatory approval, it could become available within the next few years. Patients currently struggling with frequent injections or inadequate vision improvement on existing treatments may have a meaningful new option that requires fewer visits while delivering better outcomes. For now, anyone with diabetic macular edema or wet age-related macular degeneration should discuss these emerging findings with their eye care provider to understand how they might apply to their individual situation .